Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)

Plane landing

CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in case of acute severe hypertension. CLEVIPREX is a ready-to-use option and has a ~1-minute half-life.1
How It Works

Register today for our 2024 Stroke Month Webinar: BP Control in Stroke!
Efficacy icon

BP reduction in a range of patients and clinical settings1-5

Proven efficacy in:

  • Perioperative hypertension
  • Acute severe hypertension
  • Intracerebral hemorrhage (ICH)
Safety icon

Established safety profile in multiple clinical trials2,3,6

CLEVIPREX demonstrated safety vs:

  • Nicardipine in postoperative hypertension
  • Sodium nitroprusside and nitroglycerin in perioperative hypertension
  • Placebo in perioperative hypertension
Time to effect icon

Rapidly lowers arterial BP with fast onset and offset1

  • Titratable, fast onset of action (within 2 minutes of initiation)
  • ~1-minute half-life
  • Metabolized independent of renal or hepatic function
Vial icon

Non–weight-based dosing1

CLEVIPREX dosing is also:

  • A low infusion volume1
  • Available as ready-to-use 50- and 100-mL vials1

Low-volume dosing option1

Excessive fluid intake may lead to adverse outcomes in critically ill patients7,8:

  • Consider the results of the ECLIPSE trials
  • See how infusion volumes varied between hypertensive agents in the postoperative setting

CLEVIPREX has not been studied or proven to impact fluid overload.

Access resources for CLEVIPREX

Watch KOL videos, download a summary of the American Heart Association/American Stroke Association (AHA/ASA) Guidelines, and more. Go to resources